More widespread expression of hERG protein in tumors (e.g. colorectal or endometrial cancer) and cancerous cells (e.g. acute myologenous or chronic lymphocytic leukemia) [12] suggests potential significance of hERG-based anticancer therapy beyond glioblastoma that warrants further exploration, carefully considering the significance of the individual cellular context for regulation of cell death and proliferation. Here, KCNH2 is linked to B-cell chronic lymphocytic leukemia.